Floatz logo

Darotamide

High Risk Prostate Cancer

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

513 Active assets in the High Risk Prostate Cancer cohort.

Asset / SponsorPhaseRating
Avodart
Bay State Clinical Trials, Inc.
Phase 4BBB
Desflurane
Peter MacCallum Cancer Centre, Australia
Phase 4BBB
Degarelix
Bayer
Phase 4BBB
PROPOFOL
Peter MacCallum Cancer Centre, Australia
Phase 4BBB
AVOLVE
Masonic Cancer Center, University of Minnesota
Phase 4BB

View all 50 →

Same molecule, other indications

Darotamide is also rated in:

Intense Endocrine TherapyDormant
CCC
Indicative ·
53 / 100
View asset →
Neoadjuvant TherapyDormant
CCC
Indicative ·
51 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →